Top in cardiology: Trial updates from Heart Rhythm 2024

Results from the PREDIMAR trial revealed that, among patients with atrial fibrillation who underwent ablation, following an extra-virgin olive oil-enriched Mediterranean diet reduced the risk for arrhythmia recurrence at 18 months.

Researchers reported the findings at Heart Rhythm 2024.

“We should recommend a Mediterranean diet enriched with extra-virgin olive oil to patients with paroxysmal atrial fibrillation who have been treated with an ablation to avoid or to reduce the recurrences after the procedure,” Maria Teresa Barrio-Lopez, MD, PhD, a cardiologist at University Hospital HM Montepríncipe in Madrid, told Healio.

It was the top story in cardiology last week.

In another top story, researchers found that tailored ablation guided by AI improved 1-year outcomes for patients with persistent atrial fibrillation.

Read these and more top stories in cardiology below:

Olive oil-enriched Mediterranean diet may lower risk for arrhythmia recurrence

In patients with atrial fibrillation who had ablation, those assigned a Mediterranean diet enriched with extra-virgin olive oil were less likely to have arrhythmia recurrence than those with no dietary restrictions, researchers reported. Read more.

AI-guided cardiac ablation improves 1-year outcomes in persistent atrial fibrillation

Tailored ablation guided by AI was linked to better 1-year outcomes than pulmonary vein isolation alone for patients with persistent atrial fibrillation, according to the results of the TAILORED-AF trial presented at Heart Rhythm 2024. Read more.

Is it time to deprescribe lifetime beta-blockers for chronic coronary disease?

Over the last 50 years, revascularization and pharmacotherapeutic innovations have led to significant reductions in major adverse cardiovascular events associated with both acute and chronic coronary diseases. Read more.

Pulsed field ablation for AF may reduce arrhythmia burden better than thermal ablation

Pulsed field ablation lowered the odds of high residual atrial arrhythmia burden compared with thermal ablation for patients with atrial fibrillation at 1 year, according to a subanalysis of the ADVENT trial presented at Heart Rhythm 2024. Read more.

HRS: Return-to-play decision for athletes with arrhythmias should be individualized

For athletes with arrhythmias, the return-to-play decision should be individualized based on appropriate risk assessment and treatment and the shared decision-making process should be used, according to a new expert statement. Read more.